Stellix Aspire 2025 Event Brief
Axendia was pleased to be invited to cover Stellix Aspire 2025, an exclusive event where thought leaders and executives gathered to advance sustainable life science innovation, at the Stellix Corporate Headquarters in Foxborough, MA, on April 10th.
Highlighted themes from the event:
- Connecting across ecosystem with the patient at the center
- An immersive customer experience
- Innovating with the patient in mind
- The role of AI in operational efficiencies
- Cross-disciplinary convergence
The Stellix Group is “an employee-owned portfolio of companies with a common vision of a world where accessible science and technology improve human well-being and the environment.” Stellix is composed of NECI (Emerson Impact Partner), Stellix Global Services (Industry 4.0 services provider), Zaether (digital life science business transformation provider), and Kynota (bioreactor management and insights software platform). Stellix is answering a demand for more practical solutions from the life sciences industry by bringing a diverse partner ecosystem backed by solid use cases and a portfolio of brands with expertise in life sciences process and manufacturing technologies and digital transformation.
Connecting Across the Ecosystem with the Patient at the Center
Stellix Aspire was an event designed to showcase cutting-edge digital, AI and data-driven strategies while fostering innovation through immersive, persona-driven experiences and collaborative problem-solving. With a focus on eliminating outdated models like the technology proof-of-concept, the event bridged physical and digital realms to demonstrate the possibility of tangible and transformative outcomes in life sciences.
To illustrate the importance of human collaboration in that mission, Stellix invited guests from 80+ organizations across biotech and pharma companies, technology and industry trade organizations, and technology vendors to connect with each other using high-tech badges and share their feedback digitally on the content covered during the event. Post event, the data captured was shared with each participant in a personalized communication.
Customer Experience Center and Future Lab Launch
Walking through the newly launched Customer Experience Center, the audience was presented a video depiction showcasing these possibilities with a personalized medicine scenario taking place in real-time: a patient receives a critical diagnosis, and across a digitalized network between healthcare providers, pharma companies and clinical sites, a treatment paradigm is delivered, and a patient is spared the grueling travails of endless trial and error. The video narrative challenges us to consider that this is not (and should not be) that far off in the future. The technology is there.
The attendees then provided their inputs around top business challenges that prevent progress towards the vision expressed in the video. The data was gathered by role, allowing Stellix to include these insights in the personalized post event summary.
Attendees then moved on to the Future Lab, a representative production space enabled by augmented reality that served up the digital and hardware technologies that can break down silos and move the industry beyond these hurdles.
Innovating with the Patient in Mind
The notion of patient-centeredness was reinforced during the Community Fireside Chat hosted by Jason Cordeiro, MassBio Chief Operating & Innovation Officer, with panelist, Shaylee Boger, Patient Advocate, who chronicled her journey as a rare disease patient. The emphasis Shaylee imparted was the need for focus not just on treating an illness but to think about the patient as an individual. Treatments are not viable if they simply keep disease at bay. The focus needs to be on real-world endpoints, taking into account the myriad of comorbidities that most rare disease patients are managing along with quality-of-life endpoints like being able to pursue career aspirations, fully engage in hobbies and fulfilling social interactions. Shaylee’s hope was that AI will open the door for earlier diagnosis and improved treatment across disease constellations, with the hypothesis that the advocacy and work being done today is paving an easier way for future generations.
patient advocacy in the life sciences industry. Source: Stellix
The Role of AI
John Seffernick, SVP, Strategy and Technology, Stellix, led an AI panel discussion with seasoned industry veterans from Takeda, Spark Therapeutics (acquired by Roche), Excelra, and AI start-ups Dash Bio and CrossStitch.AI. Each panelist remarked on the resounding progress that has been realized in the past few years with well-established use cases enabling administrative efficiencies, especially with the use of generative AI. A prevailing fear of relying too heavily on generative AI and agentic AI was challenged by some of the panelists who stated that we have to acknowledge what processes humans are simply not all that good at, an example being SOP writing. David Johnson from Dash Bio remarked that an underlying issue is that we generally don’t trust our people, which makes it counterintuitive to put trust in AI. He went on to provide the example of SOP writing, saying that if humans are inherently limited in drafting robust SOPs, then how can we measure the efficacy of AI models in carrying out those SOPs? Others on the panel agreed that this is where data comes into play. Humans will more than likely remain in the loop to some degree, but you need to put to the test to what degree (or how often) a human must override an AI model before you can comment on the value or reliability of an AI model. Johnson added that one of the real hindrances to assessing ROI from AI is the fundamental lack of process understanding prior to applying AI. It reinforces the adage of garbage in, garbage out.
The topic of AI’s impact on the workforce was also discussed. Nishtha Jain from Takeda remarked that we need to accept that AI will replace certain aspects of our jobs at some point. As employers, we have to make sure our employees are enabled to learn how to effectively use AI and how it complements their day to day rather than living in fear of being obsoleted. Zach Stanley, Executive Director of Bioversity, a MassBio workforce training program, reinforced this notion during the Community Fireside Chat that not all jobs can or will be replaced by AI. Stanley stated that the focus of Bioversity is training students for hands-on, on-site positions. AI is proving to be an invaluable resource for these roles, helping to democratize knowledge and narrow the gap between entry and higher-level jobs.
Superconvergence
Jamie Metzl, author and futurist, delivered an impassioned keynote to close out the evening. Metzl detailed his father’s cancer diagnosis and his family’s commitment in taking control and moving beyond the status quo treatment. This experience served as the backdrop of his 2024 book, Superconvergence, which explores “how artificial intelligence, genome sequencing, gene editing, and other revolutionary technologies are transforming our lives, world, and future.” Much of what Metzl detailed reinforced earlier themes of Stellix Aspire – that the future must be about the patient, not just the technology and the science.
One of the most poignant insights Metzl shared was around the convergence of disciplines in the quest to deliver treatments and cures that have, to this point, been elusive. To illustrate this point, Metzl noted that of the five 2024 Chemistry and Physics Nobel Prize recipients, three were experts in Computer Science. As champions in the drug development space, it is our duty, Metzl stated, to dedicate “more time learning about adjacent topics – not just those in your direct line of sight.” This paradigm has significant implications for the cross-disciplinary training of future scientists. And amidst this shift, says Metzl, it is imperative that we get our arms around necessary models of governance. Denying this need will perpetuate fear, misunderstanding and misuse of these technologies despite their undeniable potential.
On a practical level, Metzl advises:
- Start with this question: what are we trying to achieve and how can new technologies help us do that better?
- Establish an aggressive learning plan for you and your organization
- Fully leverage your networks for wisdom and best practices
- Start with small bets and build up… but keep building up
- Think practically but expansively while making sure you are aligning with your values and goals
- Trust yourselves (and don’t be intimidated by technology)… you know more than you think
In Brief
Stellix CEO, Jenn Azar, both set and closed the stage for Stellix Aspire with themes of innovation, collaboration and acceleration. These pillars were exemplified with the interactive exhibits in the Stellix Customer Experience Center and with the energetic discussions taking place amongst ecosystem technology partners and industry experts in the Outcomes Lounge. With a collective understanding of the business challenges that continue to plague the industry, including organizational inertia, Stellix is poised to play a pivotal role in delivering change.
We will continue to provide updates on Stellix as they become available.
Axendia Related Content:
- Accelerating the Trajectory of Digital Sustainability in the Lab
- Accelerating Transfer with Standardized Recipe Management
- The State of Generative AI In Life Sciences: New Market Research
Ready to unlock new opportunities and drive success? Schedule an Analyst Inquiry today to explore how the latest advancements in automation, AI, and industrial autonomy can transform your business.
Visit Axendia.com or follow us on LinkedIn for more insights and updates. Together, we’ll prepare your organization for a future of resilience, adaptability, and growth.
The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.